Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 safety and efficacy trial for exebacase as a treatment for patients with chronic post-operative Staphylococcal prosthetic joint infections of knee

X
Trial Profile

A Phase 1/2 safety and efficacy trial for exebacase as a treatment for patients with chronic post-operative Staphylococcal prosthetic joint infections of knee

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exebacase (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ContraFect
  • Most Recent Events

    • 28 Aug 2023 According to a ContraFect media release, Garrett Nichols, MD, Interim Chief Medical Officer of company, will discuss data supporting the study of Exebacase in this phase 1/2 trial for CF-370 at the World Anti-Microbial (AMR) Congress 2023, which will be held in Philadelphia, PA from September 7-8, 2023.
    • 27 Jun 2023 According to a ContraFect media release, the proceeds to the company from the exercise of the existing warrants are $9.6 million that will be used to support ongoing enrollment in this trial.
    • 15 May 2023 According to a ContraFect media release, first patient dosed at the Hospices Civils de Lyon in Lyon, France, the clinical site where the study is being conducted.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top